NCT06907680

M-Gard Particulate EW Efficacy Study on Seasonal Allergic Rhinitis

A Randomized Placebo-controlled Crossover Trial Assessing the Efficacy and Safety of M-Gard Particulate EW in the Treatment of Seasonal Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to assess the efficacy and safety of M-Gard supplementation for alleviating the symptoms of allergic rhinitis.

Conditions

• Allergic Rhinitis Due to Grass Pollens

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	M-Gard	One capsule containing 250mg of M-Gard Particulate EW is taken twice daily for 14 days.
OTHER	Placebo	One capsule containing 250mg of MCC (Microcrystalline Cellulose) is taken twice daily for 14 days.

Timeline

• Start date: 2025-06-27
• Primary completion: 2026-01-29
• Completion: 2026-01-29
• First posted: 2025-04-02
• Last updated: 2026-03-06

Locations

1 site across 1 country: Australia